SynthesisCancer medicine2015
Efficacy and safety of botulinum toxin type A for treatment of Frey's syndrome: evidence from 22 published articles.
Synthesis in Cancer medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Guidelines for the Use of Botulinum Toxin in Otolaryngology From the Korean Society of Laryngology, Phoniatrics and Logopedics Guideline Task Force.Clinical and experimental otorhinolaryngology · 2023Guideline
- Pooled it
- Frey Syndrome: A Novel Classification System Based on Symptom Severity.Laryngoscope investigative otolaryngology · 2026Article
- Auriculotemporal syndrome associated with a traumatic vaginal delivery at birth.BMJ case reports · 2023Article
- The incidence of Frey syndrome and treatment with botulinum toxin in the Central Denmark Region.Laryngoscope investigative otolaryngology · 2022Article
- Preclinical Evidence for the Role of Botulinum Neurotoxin A (BoNT/A) in the Treatment of Peripheral Nerve Injury.Microorganisms · 2022Review
- Review
- Non-aesthetic uses of botulinum toxin in the head and neck.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2021Review
- The whole truth about botulinum toxin - a review.Postepy dermatologii i alergologii · 2020Review
- Review
- Graft interposition for preventing Frey's syndrome in patients undergoing parotidectomy.The Cochrane database of systematic reviews · 2019Review
- Botulinum toxin type A interrupts autophagic flux of submandibular gland.Bioscience reports · 2019Article
- Use of botulinum toxin in Frey's syndrome.Clinical case reports · 2019Article
- Botulinum toxin therapy: functional silencing of salivary disorders.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2017Review
- What is the Prognostic Significance of Ki-67 Positivity in Oral Squamous Cell Carcinoma?Journal of Cancer · 2016Article
- Mupirocin in the Treatment of Staphylococcal Infections in Chronic Rhinosinusitis: A Meta-Analysis.PloS one · 2016Article
- An Experimental Study on Botulinum Toxin Type A for the Treatment of Excessive Secretion after Submandibular Gland Transplantation in Rabbits.Journal of ophthalmology · 2016Article
- Management of parotid fistula and Frey's syndrome with Botulinum neurotoxin type A.National journal of maxillofacial surgeryArticle
- Use of botulinum toxin type A in Frey's syndrome.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Frey's syndrome (FS) is an unavoidable sequela following the surgery of the parotid gland. Although several treatment methods are available, their efficacy is short term or accompanied by unacceptable complications. In the past two decades, botulinum toxin type A (BTXA) has been widely used to treat FS. Although several systematic reviews have been reported recently, they were conflicting and with obvious deficiencies. Thus, we performed an objectively systematic review to determine whether BTXA is an effective and safe treatment for FS. A literature retrieval covering PubMed, Web of Science, Ovid, Embase and Cochrane library was performed on 16 January, 2015. Proportion meta-analysis and corresponding 95% confidence interval (CI) were performed to evaluate the efficacy and safety of BXTA in treatment of FS. A total of 499 records were retrieved and 22 articles with 23 studies were included after scrutiny by two independent authors. Statistical analyses regarding the effective rate, incidence of complications were used to estimate the efficacy and safety of BTXA. Our results suggested that the effective rate of BTXA for treatment of FS is 98.5% (95% CI = 0.971-0.994) and the incidence of complication is 3.6% (95% CI = 0.017-0.061). In conclusion, our study supports that BTXA produces meaningful benefits on the treatment of patients with FS. However, owing to lack of strong evidence, future studies with well-designed inclusion criteria and multicenter randomized controlled trials are needed to give more credible evidence, if possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.